等待開盤 07-18 09:30:00 美东时间
+7.940
+6.13%
Johnson & Johnson (NYSE:JNJ) traded higher in the premarket on Wednesday as the healthcare giant started pharma earnings season, lifting its full-year outlook after reporting better-than-expected fina...
07-16 19:04
Pelthos launches Zelsuvmi, the first FDA-approved at-home prescription gel for molluscum, shown to clear lesions in as little as two weeks.
07-10 20:13
Ligand Pharmaceuticals announced that its partner Pelthos Therapeutics has launched ZELSUVMI™, the first FDA-approved at-home treatment for molluscum contagiosum, earning Ligand a $5 million milestone payment. Ligand now owns 56% of Pelthos post-merger and is entitled to a 13% royalty on ZELSUVMI sales and up to an additional $5 million in milestones. ZELSUVMI, developed using Ligand's NITRICIL™ technology, is the first topical prescription medic...
07-10 12:00
U.S. stocks were higher, with the Dow Jones index gaining around 0.1% on Wednes...
07-09 23:06
Ligand Pharmaceuticals completed its merger with Channel Therapeutics to form Pelthos Therapeutics, which will begin trading on the NYSE American under the ticker "PTHS" on July 2, 2025. Pelthos plans to launch ZELSUVMI, a novel topical gel for treating Molluscum contagiosum infections, later this summer. Ligand invested $18 million in the combined company and will receive a 13% royalty on ZELSUVMI's worldwide sales. The merger also included a $5...
07-02 11:00
Pelthos Therapeutics Inc., formed through the merger of Channel Therapeutics and Ligand’s LNHC, will debut on the NYSE American exchange under ticker "PTHS" on July 2, 2025. The company plans to launch ZELSUVMI™, a novel topical gel for molluscum contagiosum, in July 2025. Concurrently, Pelthos secured $50.1 million in a private equity placement, including repayment of $18.8 million in prior bridge financing. The company aims to leverage its nitr...
07-02 11:00
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务,助力上市公司传播ESG理念,提升ESG可持续发展表现。点击查看【 ESG评级中...
06-27 07:00
The European Medicines Agency (EMA) has recommended the approval of nirogacestat, an oral gamma secretase inhibitor, for the treatment of adults with progressing desmoid tumors in Europe. The European Commission (EC) is expected to make a final decision by the third quarter of 2025. Nirogacestat has already been approved in the U.S. and demonstrated significant benefits in the Phase 3 DeFi trial, including improved progression-free survival and p...
06-20 12:00
Ligand Pharmaceuticals announced an Investor Day on December 9, 2025, in New York City, to discuss its strategy, investments, royalty portfolio, and financial outlook. The event will feature senior management presentations and a live webcast available on Ligand's Investor Relations website. More details, including dial-in information, will be shared closer to the event. Ligand is a biopharmaceutical company focused on advancing high-value medicin...
06-11 11:00
NextCure and LigaChem Bio announced LNCB74, a Phase 1 B7-H4 targeted ADC, is being studied as monotherapy for advanced solid tumors. The trial, currently enrolling in dose escalation, will also include expansion and optimization phases. Results will be presented at the 2025 ASCO Annual Meeting on June 2. LNCB74 has shown promising safety and anti-tumor activity in preclinical studies, highlighting B7-H4's potential as a target for ADC therapy. *...
05-29 20:05